Citations

Showing 10 of 108094 citations.

Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual
Gertz, Morie A. , Gertz, Morie A.

Mayo Clinic

Journal of Clinical Oncology | June 14, 2022 | Volume: 40 | Issue: 23 | Pages: 2600-2608

10.1200/jco.22.00495 | PMID 35700418 Get It

With the introduction of multiple new effective therapeutic options for the treatment of macroglobulinemia, a structured approach to management of this rare lymphoma is currently needed. A review of phase II and III treatment trials over the past 20 years was performed, and high-quality trials are summarized in this manuscript. Because of the lack of large prospective trials comparing different classes of therapy, a uniform recommendation applicable to all patients cannot be made, and the approach must be individualized incorporating patient preferences, comorbidities, and the range of therapeutic toxicities. Therapeutic options for patients with newly diagnosed and previously treated macroglobulinemia are presented on the basis of the best available evidence in the literature.
Is it a Flare? Acute Appendicitis in Ulcerative Colitis Patient Found on Routine Screening Colonoscopy
Jordan, Ariel , Maraj, Bharat , Kinnucan, Jami

Mayo Clinic

Inflammatory Bowel Diseases | June 14, 2022 | Volume: 28 | Issue: 9 | Pages: 1472-1473

10.1093/ibd/izac112 | PMID 35700277 Get It

Prevalence, Predictors, and Oncologic Outcomes of Pelvic Organ Involvement in Women Undergoing Radical Cystectomy
Benidir, Tarik , Cheville, John C. , Packiam, Vignesh T. , Shah, Paras , Frank, Igor, Tollefson, Matthew K. , Thompson, R. Houston, Karnes, R. Jeffrey , Thapa, Prabin , Kulkarni, Girish S. , Boorjian, Stephen A. , Avulova, Svetlana

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 14, 2022 | Volume: 147 | Issue: 2 | Pages: 202-207

10.5858/arpa.2021-0409-oa | PMID 35700531 Get It

Context.— In women, radical cystectomy includes removal of the bladder, uterus, fallopian tubes, ovaries, and anterior vaginal wall, yet contiguous extension of urothelial carcinoma to all pelvic organs is rare and routine removal may be unnecessary. Objective.— To study pelvic organ involvement in women at radical cystectomy and investigate oncologic outcomes. Design.— Women with bladder cancer who underwent radical cystectomy at the Mayo Clinic and University of Toronto (1980–2018) were evaluated. Cancer-specific survival (CSS) was estimated with the Kaplan-Meier method; comparisons were made with the log-rank test. Associations with CSS were evaluated with Cox proportional hazard modeling. Results.— A total of 70 women with pT4a and 83 with pT3b cancer were studied. Organs involved were vagina (n = 41 of 70; 58.6%), uterus (n = 26 of 54; 48.1%), cervix (n = 15 of 54; 27.8%), fallopian tubes (n = 10 of 58; 17.2%), and ovaries (n = 7 of 58; 12.1%); 22 of 58 patients (37.9%) had >1 organ involved. Of 70 with pT4a cancer, 64 were available for survival analysis by 3 pelvic organ groups: vaginal only, vaginal and/or cervical/uterine, and vaginal and/or cervical/uterine and/or fallopian tubes/ovarian involvement. Three-year CSS for vaginal involvement only was 39%; it was 14% if cervical/uterine involvement, and <1% if fallopian tube/ovarian involvement was included (P = .02). Among 20 women with pT4aN0/Nx and vaginal involvement only, 3-year CSS for vaginal involvement was 50%, whereas among 48 women with pT3bN0/Nx cancer, 3-year CSS was 58%, P = .70. Conclusions.— Isolated vaginal involvement should be separated from uterine and/or adnexal extension of urothelial carcinoma at pathologic staging. Direct ovarian extension is rare and routine removal may be unnecessary.
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma
Ho, Matthew , Moscvin, Maria , Low, Soon Khai , Evans, Benjamin , Close, Sara, Schlossman, Robert, Laubach, Jacob P. , Prada, Claudia, Glotzbecker, Brett, Richardson, Paul G. , Ho, Matthew , Richardson, Paul Gerard Guy , Bianchi, Giada

Mayo Clinic

Leukemia & Lymphoma | June 14, 2022 | Volume: 63 | Issue: 10 | Pages: 2403-2412

10.1080/10428194.2022.2084729 | PMID 35699975 Get It

Physical Symptoms, Distress, and Functional Disability in Youth With Chronic Orthostatic Intolerance
Owens, Michele S Tsai, Biggs, Bridget K. , Fahrenkamp, Amy J., Geske, Jennifer R. , Hofschulte, Deanna R., Harbeck‐Weber, Cynthia , Geske, Jennifer, Fischer, Philip R. , Biggs, Bridget K , Geske, Jennifer , Owens, Michele Tsai , Harbeck‐Weber, Cynthia

Mayo Clinic

Journal of Pediatric Psychology | June 14, 2022 | Volume: 47 | Issue: 10 | Pages: 1185-1194

10.1093/jpepsy/jsac052 | PMID 35699566 Get It

AbstractObjectiveYouth with chronic orthostatic intolerance (OI) can experience significant physical, social, and academic functional debilitation. Previous studies have indicated associations among symptom severity, psychosocial factors, and functional disability. However, empirically tested models explaining how different medical and psychosocial factors may contribute to functional disability are lacking. The current cross-sectional study aimed to evaluate mediation, moderation, and additive models of the effect of physical symptoms and psychological distress on functional disability.MethodsOne hundred and sixty-five youth (13–22 years old) undergoing medical evaluation of chronic OI symptoms completed measures of autonomic dysfunction symptom severity, depressive and anxiety symptoms, and functional disability. Models were evaluated using tests of indirect effects and linear and logistic regression analyses.ResultsResults supported the mediation and additive effects models for depressive symptoms. Mediation, moderation, and additive models for hypothesized effects of anxiety symptoms were not supported.ConclusionsResults provide preliminary support for models in which OI symptoms affect functional debility via their effects on mood and in which depressive symptoms have unique and additive effects on functioning. Findings lay the foundation for longitudinal and experimental evaluation of biopsychosocial models of functional disability in youth with chronic OI and related conditions. Implications include the importance of a biopsychosocial conceptualization of OI symptoms and debility as a complex interplay of factors rather than as a purely physiological or psychological process.
Racial Disparities in the Utilization of Shoulder Arthroplasty in the United States
Farley, Kevin X. , Dawes, Alexander , Wilson, Jacob M. , Toston, Roy J. , Hurt, John , Gottschalk, Michael B. , Navarro, Ronald A. , Dawes, Alexander M , Hurt, John T , Wagner, Eric R , Wagner, Eric R.

Mayo Clinic

JBJS Open Access | June 14, 2022 | Volume: 7 | Issue: 2 | Pages: No page available

10.2106/jbjs.oa.21.00144 | PMID 35673617 Get It

Background: As the incidence of shoulder arthroplasty rises at exponential rates, race is an important consideration, as racial disparities have been reported in lower-extremity arthroplasty in the United States. Our study sought to examine these disparities. Methods: Using the National Inpatient Sample (NIS) database, all anatomic total shoulder arthroplasty (aTSA) and reverse total shoulder arthroplasty (RSA) procedures from 2011 to 2017 were analyzed. The patients were divided into the Black, Hispanic, and White groups. Results: Overall, 91.4% of the patients undergoing any shoulder arthroplasty procedure were White, 4.75% were Black, and 3.85% were Hispanic. Age and sex-standardized RSA utilization rates (per 100,000) in White patients increased by 139% from 6.94 in 2011 to 16.60 in 2017. The disparity for Black patients, compared with White patients, was 118% in 2011 and 124% in 2017; the disparity for Hispanic patients was 112% in 2011 and 103% in 2017. Similar disparities in aTSA utilization rates were seen; when compared with White patients, there was a 150% disparity in 2011 and a 197% disparity in 2017 for Black patients, and a 169% disparity in 2011 and a 262% disparity in 2017 for Hispanic patients. Finally, Blacks had a higher rate of non-home discharge, longer length of stay, and higher overall costs, while Hispanics had a longer length of stay and higher cost than Whites. Conclusions: Despite many efforts to reduce racial disparities in health-care utilization, the chasm in shoulder arthroplasty in the United States appears to be large and widening further. The exponential increase in utilization of shoulder arthroplasty has not been shared equally among races, and the disparities are larger than those reported in lower-extremity arthroplasty.
Practical considerations in epilepsy neurostimulation
Simpson, Hugh D. , Schulze‐Bonhage, Andreas , Cascino, Gregory D. , Fisher, Robert S. , Jobst, Barbara C. , Sperling, Michael R. , Lundstrom, Brian N. , Schulze-Bonhage, Andreas , Sperling, Michael R , Lundstrom, Brian Nils , Fisher, Robert , Jobst, Barbara

Mayo Clinic

Epilepsia | June 14, 2022 | Volume: 63 | Issue: 10 | Pages: 2445-2460

10.1111/epi.17329 | PMID 35700144 Get It

Abstract Neuromodulation is a key therapeutic tool for clinicians managing patients with drug‐resistant epilepsy. Multiple devices are available with long‐term follow‐up and real‐world experience. The aim of this review is to give a practical summary of available neuromodulation techniques to guide the selection of modalities, focusing on patient selection for devices, common approaches and techniques for initiation of programming, and outpatient management issues. Vagus nerve stimulation (VNS), deep brain stimulation of the anterior nucleus of the thalamus (DBS‐ANT), and responsive neurostimulation (RNS) are all supported by randomized controlled trials that show safety and a significant impact on seizure reduction, as well as a suggestion of reduction in the risk of sudden unexplained death in epilepsy (SUDEP). Significant seizure reductions are observed after 3 months for DBS, RNS, and VNS in randomized controlled trials, and efficacy appears to improve with time out to 7 to 10 years of follow‐up for all modalities, albeit in uncontrolled follow‐up or retrospective studies. A significant number of patients experience seizure‐free intervals of 6 months or more with all three modalities. Number and location of epileptogenic foci are important factors affecting efficacy, and together with comorbidities such as severe mood or sleep disorders, may influence the choice of modality. Programming has evolved—DBS is typically initiated at lower current/voltage than used in the pivotal trial, whereas target charge density is lower with RNS, however generalizable optimal parameters are yet to be defined. Noninvasive brain stimulation is an emerging stimulation modality, although it is currently not used widely. In summary, clinical practice has evolved from those established in pivotal trials. Guidance is now available for clinicians who wish to expand their approach, and choice of neuromodulation technique may be tailored to individual patients based on their epilepsy characteristics, risk tolerance, and preferences.
Traumatic Brain Injury and Risk of Alzheimer’s Disease and Related Dementias in the Population
Ransom, Jeanine E. , Mandrekar, Jay , Turcano, Pierpaolo , Savica, Rodolfo , Brown, Allen W. , Mielke, Michelle M.

Mayo Clinic

Journal of Alzheimer's Disease | June 14, 2022 | Volume: 88 | Issue: 3 | Pages: 1049-1059

10.3233/jad-220159 | PMID 35723103 Get It

Background: Epidemiological studies examining associations between traumatic brain injury (TBI) and Alzheimer’s disease and related dementias (ADRD) have yielded conflicting results, which may be due to methodological differences. Objective: To examine the relationship between the presence and severity of TBI and risk of ADRD using a population-based cohort with medical record abstraction for confirmation of TBI and ADRD. Methods: All TBI events among Olmsted County, Minnesota residents aged > 40 years from 1985–1999 were confirmed by manual review and classified by severity. Each TBI case was randomly matched to two age-, sex-, and non-head injury population-based referents without TBI. For TBI events with non-head trauma, the Trauma Mortality Prediction Model was applied to assign an overall measure of non-head injury severity and corresponding referents were matched on this variable. Medical records were manually abstracted to confirm ADRD diagnosis. Cox proportional hazards models examined the relationship between TBI and severity with risk of ADRD. Results: A total of 1,418 residents had a confirmed TBI (865 Possible, 450 Probable, and 103 Definite) and were matched to 2,836 referents. When combining all TBI severities, the risk of any ADRD was significantly higher for those with a confirmed TBI compared to referents (HR = 1.32, 95% CI: 1.11, 1.58). Stratifying by TBI severity, Probable (HR = 1.42, 95% CI: 1.05, 1.92) and Possible (HR = 1.29, 95% CI: 1.02–1.62) TBI was associated with an increased risk of ADRD, but not Definite TBI (HR = 1.22, 95% CI: 0.68, 2.18). Conclusion: Our analyses support including TBI as a potential risk factor for developing ADRD.
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
Macauda, Angelica , Clay‐Gilmour, Alyssa , Hielscher, Thomas , Kruszewski, Marcin , Orlowski, Robert Z. , Kumar, Shaji , Ziv, Elad , Brown, Elizabeth E. , Waller, Rosalie G. , Machiela, Mitchell J. , Camp, Nicola J. , Raźny, Małgorzata , Várkonyi, Judit , Piredda, Chiara , Pelosini, Matteo , Belachew, Alem A. , Rybicka‐Ramos, Malwina, Goldschmidt, Hartmut , Tomczak, Waldemar , Sáinz, Juan , Butrym, Aleksandra , Wątek, Marzena , Iskierka‐Jazdzewska, Elżbieta , Buda, Gabriele , Robinson, Dennis P. , Dudziński, Marek , Martínez‐López, Joaquín , Reis, Rui Manuel , Weinhold, Niels , Bhatti, Parveen , Carvajal‐Carmona, Luis G. , Zawirska, Daria , Mazur, Grzegorz , Berndt, Sonja I. , Campa, Daniele , Vachon, Celine M. , Martinez-Lopez, Joaquin , Griffin, R. L. , Kruszewski, Marcin , Orlowski, Robert Z. , Kumar, Shaji K , Ziv, Elad , Försti, Asta , Waller, Rosalie G , Machiela, Mitchell J , Chanock, Stephen Jacob , Camp, Nicola J , Rymko, Marcin , Raźny, Małgorzata , Cozen, Wendy , Piredda, Chiara , Pelosini, Matteo , Belachew, Alem A , Subocz, Edyta , Giles, Graham G , Milne, Roger L , Zaucha, Jan Maciej , Vangsted, Annette Juul , Goldschmidt, Hartmut , Rajkumar, S Vincent , Tomczak, Waldemar , Sainz, Juan , Watek, Marzena , Iskierka-Jazdzewska, Elżbieta , Buda, Gabriele , Dudziński, Marek , Martinez-Lopez, Joaquin , Sinnwell, Jason P , Slager, Susan L , Reis, Rui Manuel , Weinhold, Niels , Bhatti, Parveen , Carvajal-Carmona, Luis G , Zawirska, Daria , Mazur, Grzegorz , Berndt, Sonja I , Vachon, Celine M. , Canzian, Federico , Martinez-Lopez, Joaquin , Butrym, Aleksandra , Griffin, Rosalie , Hildebrandt, Michelle A.T. , Orciuolo, Enrico , Försti, Asta , Rymko, Marcin , Cozen, Wendy , Subocz, Edyta , Hemminki, Kari , Giles, Graham G. , Milne, Roger L. , Hofmann, Jonathan N. , Zaucha, Jan Maciej , Rajkumar, S. Vincent , Jurczyszyn, Artur , Sinnwell, Jason P. , Slager, Susan L. , Jamroziak, Krzysztof , Norman, Aaron D. , Canzian, Federico

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 14, 2022 | Volume: 31 | Issue: 9 | Pages: 1863-1866

10.1158/1055-9965.epi-22-0043 | PMID 35700034 Get It

Abstract Background: Genome-wide association studies (GWAS) of multiple myeloma in populations of European ancestry (EA) identified and confirmed 24 susceptibility loci. For other cancers (e.g., colorectum and melanoma), risk loci have also been associated with patient survival. Methods: We explored the possible association of all the known risk variants and their polygenic risk score (PRS) with multiple myeloma overall survival (OS) in multiple populations of EA [the International Multiple Myeloma rESEarch (IMMEnSE) consortium, the International Lymphoma Epidemiology consortium, CoMMpass, and the German GWAS] for a total of 3,748 multiple myeloma cases. Cox proportional hazards regression was used to assess the association between each risk SNP with OS under the allelic and codominant models of inheritance. All analyses were adjusted for age, sex, country of origin (for IMMEnSE) or principal components (for the others) and disease stage (ISS). SNP associations were meta-analyzed. Results: SNP associations were meta-analyzed. From the meta-analysis, two multiple myeloma risk SNPs were associated with OS (P < 0.05), specifically POT1-AS1-rs2170352 [HR = 1.37; 95% confidence interval (CI) = 1.09–1.73; P = 0.007] and TNFRSF13B-rs4273077 (HR = 1.19; 95% CI = 1.01–1.41; P = 0.04). The association between the combined 24 SNP MM-PRS and OS, however, was not significant. Conclusions: Overall, our results did not support an association between the majority of multiple myeloma risk SNPs and OS. Impact: This is the first study to investigate the association between multiple myeloma PRS and OS in multiple myeloma.
Faculty Opinions recommendation of Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies.
Caviness, John N.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 14, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742165492.793593425 Get It